1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: * chronic kidney disease (stage iv or receiving dialysis) * cirrhosis (child-pugh class b or greater) * porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. history of alcohol abuse within the last 6 months. 10. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). 11. history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. 12. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 13. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 14. inability or unwillingness to be followed up for the study period. 15. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 16. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. 17. confirmed vaccination against sars-cov-2.

1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: * chronic kidney disease (stage iv or receiving dialysis) * cirrhosis (child-pugh class b or greater) * porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. history of alcohol abuse within the last 6 months. 10. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). 11. history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. 12. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 13. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 14. inability or unwillingness to be followed up for the study period. 15. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 16. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. 17. confirmed vaccination against sars-cov-2.

pregnant or lactating women. pcr and/or serology confirmed sars-cov-2 infection at screening. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). self-reported presence or history of any of the following conditions: chronic kidney disease (stage iv or receiving dialysis) cirrhosis (child-pugh class b or greater) porphyria cutanea tarda. currently on treatment for epilepsy or other seizure disorder. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. current enrolment in another covid-19 prevention trial. history of alcohol abuse within the last 6 months. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. inability or unwillingness to be followed up for the study period. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. confirmed vaccination against sars-cov-2.

pregnant or lactating women. pcr and/or serology confirmed sars-cov-2 infection at screening. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). self-reported presence or history of any of the following conditions: chronic kidney disease (stage iv or receiving dialysis) cirrhosis (child-pugh class b or greater) porphyria cutanea tarda. currently on treatment for epilepsy or other seizure disorder. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. current enrolment in another covid-19 prevention trial. history of alcohol abuse within the last 6 months. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. inability or unwillingness to be followed up for the study period. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. confirmed vaccination against sars-cov-2.

1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: - chronic kidney disease (stage iv or receiving dialysis) - cirrhosis (child-pugh class b or greater) - porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. history of alcohol abuse within the last 6 months. 10. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). 11. history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. 12. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 13. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 14. inability or unwillingness to be followed up for the study period. 15. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 16. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. 17. confirmed vaccination against sars-cov-2.

1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: - chronic kidney disease (stage iv or receiving dialysis) - cirrhosis (child-pugh class b or greater) - porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin,st. john's wort or any herbal products which may potentially decrease the concentration of the imp. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. history of alcohol abuse within the last 6 months. 10. having history or have risk factors for brady-arrhythmias (those with undiagnosed cardiac conditions). 11. history of malignancies in the last 5 years, excluding in-situ or non-invasive malignancies. 12. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 13. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 14. inability or unwillingness to be followed up for the study period. 15. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 16. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. 17. confirmed vaccination against sars-cov-2.

1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: - chronic kidney disease (stage iv or receiving dialysis) - cirrhosis (child-pugh class b or greater) - porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, or st. john's wort. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 11. inability or unwillingness to be followed up for the study period. 12. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 13. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results.

1. pregnant or lactating women. 2. pcr and/or serology confirmed sars-cov-2 infection at screening. 3. current symptoms of covid-19 disease (including, but not limited to, fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia, or diarrhea). 4. self-reported presence or history of any of the following conditions: - chronic kidney disease (stage iv or receiving dialysis) - cirrhosis (child-pugh class b or greater) - porphyria cutanea tarda. 5. currently on treatment for epilepsy or other seizure disorder. 6. currently on treatment with a protease inhibitor-based antiretroviral regimen, or efavirenz, or on treatment with amiodarone, carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, or st. john's wort. 7. known hypersensitivity or specific contraindications to the use of any of the active drugs in the treatment arms or similar compounds. 8. current enrolment in another covid-19 prevention trial. 9. concurrent or recent (within 3 months) participation in other research with a compound likely to interfere with any of the investigational products. 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the volunteer or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 11. inability or unwillingness to be followed up for the study period. 12. personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. (personnel employed at a study site, but not directly involved in the conduct of the study, who would like to participate in the study, may only do so if they are enrolled in the study through a different site at which they are not employed.) 13. participant is judged by the investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results.